Cyberonics, Sorin Seek Critical Mass With Merger
This article was originally published in The Gray Sheet
Executive Summary
The yet-to-be-named combined company is predicting big opportunities, particularly, heart failure, sleep apnea and cardiac surgery.
You may also be interested in...
Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
Boston Scientific and Cyberonics report disappointing data on vagus nerve stimulation to treat heart failure at the European Society of Cardiology conference in Barcelona. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.